Ensysce Biosciences, Inc (ENSC) News
Filter ENSC News Items
ENSC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ENSC News Highlights
- For ENSC, its 30 day story count is now at 3.
- Over the past 8 days, the trend for ENSC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ENSC are AZ.
Latest ENSC News From Around the Web
Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 /Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 ... |
Ensysce Biosciences Announces Key Efficacy Data for Lead AnalgesicResults Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity ReductionPF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, ... |
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day PodcastPHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.CEO of the Company, ... |
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note FinancingAdditional Funding from Investors Validates Company's MissionSAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve ... |
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United StatesCollaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the ... |
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~~ Trial Results Expected in December 2023 ~SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ... |
ENSC Releases Earnings and Highlights ProgressBy Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Earnings Update • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon |
Ensysce Biosciences Reports Third Quarter 2023 Financial ResultsPF614-201 Clinical Study Results Expected by End of YearSAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription ... |
Ensysce Biosciences Secures $1.7 Million Convertible Note FinancingAdditional Funding from Investor Cohort Validates Company's MissionSAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage company applying transformative ... |
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR FormulationSAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative ... |